Identification

Name
Doxylamine
Accession Number
DB00366
Description

Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Thumb
Weight
Average: 270.3694
Monoisotopic: 270.173213336
Chemical Formula
C17H22N2O
Synonyms
  • 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
  • 2-Dimethylaminoethoxyphenylmethyl-2-picoline
  • Dossilamina
  • Doxilamina
  • Doxilminio
  • Doxylamine
  • Doxylaminum
  • N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
  • Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether

Pharmacology

Indication

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.

Mechanism of action

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
UMuscarinic acetylcholine receptor
antagonist
Humans
UNuclear receptor subfamily 1 group I member 3Not AvailableHumans
Absorption

Readily absorbed via the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half-life

10 hours

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Signs of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Doxylamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acebutolol.
AcetazolamideDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetazolamide.
AcetophenazineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetophenazine.
AclidiniumThe risk or severity of adverse effects can be increased when Doxylamine is combined with Aclidinium.
AcrivastineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acrivastine.
AdenosineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Adenosine.
AgomelatineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
AjmalineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ajmaline.
AlfentanilDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Doxylamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol. Co-administration may increase drowsiness and fall risk.

Products

Product Ingredients
IngredientUNIICASInChI Key
Doxylamine succinateV9BI9B5YI2562-10-7KBAUFVUYFNWQFM-UHFFFAOYSA-N
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
7 Select Sleep AidTablet25 mg/1Oral7-Eleven2014-08-052022-02-28US flag
Aldex ANTablet, chewable5 mg/1OralPernix Therapeutics2010-01-202012-10-31US flag
Basic Care Sleep AidTablet25 mg/1OralAmazon.com Services LLC2020-06-02Not applicableUS flag
Basic Care Sleep AidTablet25 mg/1OralL. Perrigo Company2018-03-06Not applicableUS flag
Berkley and Jensen Sleep AidTablet25 mg/1OralBJWC2018-08-06Not applicableUS flag
Care One Sleep AidTablet25 mg/1OralAmerican Sales Company2004-06-292018-12-01US flag
CareOne Nighttime Sleep AidTablet25 mg/1OralAmerican Sales Company2016-05-06Not applicableUS flag
Equaline Sleep AidTablet25 mg/1OralSupervalu2004-08-102015-11-01US flag
Equate sleep aidTablet25 mg/1OralWalmart Stores1997-02-252014-01-27US flag
Good Neighbor Pharmacy Sleep AidTablet25 mg/1OralAmerisource Bergen1997-06-26Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
7 Select Night Time ReliefDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (15 mg/1)Capsule, liquid filledOral7-Eleven2014-04-172020-07-31US flag
7 Select Night Time ReliefDoxylamine succinate (12.5 mg/30mL) + Acetaminophen (650 mg/30mL) + Dextromethorphan hydrobromide monohydrate (30 mg/30mL)SolutionOral7-Eleven2014-08-052021-03-31US flag
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralCVS Health2017-11-30Not applicableUS flag
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralCvs Pharmacy,inc2017-07-07Not applicableUS flag
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and DOXYLAMINE SUCCINATEDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (15 mg/1)Capsule, liquid filledOralJ.P. BUSINESS ENTERPRISE2014-12-01Not applicableUS flag
Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine HydrochlorideDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralGranules India Limited2017-07-07Not applicableUS flag
Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine hydrochlorideDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralHealthlife of Usa2017-07-072017-07-07US flag
ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, and DOXYLAMINE SUCCINATEDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (15 mg/1)Capsule, liquid filledOralSpirit Pharmaceuticals, Llc2009-10-15Not applicableUS flag
Acetaminophen,Dextromethorphan,DoxylamineDoxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1)Capsule, liquid filledOralAgile Pharmachem2014-05-01Not applicableUS flag
Acetaminophen/pseudoephedrine/dextromethorphan/doxylamineDoxylamine succinate (6.25 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada flag

Categories

ATC Codes
R06AA09 — DoxylamineR06AA59 — Doxylamine, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzylethers
Direct Parent
Benzylethers
Alternative Parents
Pyridines and derivatives / Heteroaromatic compounds / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amine / Aromatic heteromonocyclic compound / Azacycle / Benzylether / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amine, pyridines (CHEBI:51380)

Chemical Identifiers

UNII
95QB77JKPL
CAS number
469-21-6
InChI Key
HCFDWZZGGLSKEP-UHFFFAOYSA-N
InChI
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
IUPAC Name
dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
SMILES
CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1

References

General References
Not Available
Human Metabolome Database
HMDB0001936
KEGG Drug
D02327
PubChem Compound
3162
PubChem Substance
46506354
ChemSpider
3050
BindingDB
50239996
RxNav
3642
ChEBI
51380
ChEMBL
CHEMBL1004
Therapeutic Targets Database
DAP000859
PharmGKB
PA449419
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxylamine
AHFS Codes
  • 04:04.04 — Ethanolamine Derivatives
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentMorning Sickness1
3CompletedPreventionHyperemesis Gravidarum / Pregnancy1
3CompletedTreatmentHerpes Simplex Labialis1
3CompletedTreatmentNausea and Vomiting of Pregnancy1
1CompletedNot AvailableAllergic Rhinitis (AR) / Upper Respiratory Tract Infection1
1WithdrawnTreatmentBioavailability1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amend
  • Centurion Labs
  • Chattem Chemicals Inc.
  • Deltex Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Perrigo Co.
Dosage Forms
FormRouteStrength
Tablet, chewableOral5 mg/1
Tablet, effervescentOral
Tablet, extended releaseOral
Capsule; kitOral
TabletOral
SolutionOral
Tablet, delayed releaseOral
PowderOral
TabletOral25 mg/1
Syrup15 mg/15mL
Tablet, effervescentOral25 mg
SyrupOral
Tablet, orally disintegratingOral25 mg
SolutionOral10 mg
Capsule, liquid filledOral
CapsuleOral
Capsule, gelatin coatedOral
Tablet, film coatedOral
Tablet, coatedOral
Tablet, film coatedOral10 mg
Capsule, delayed releaseOral10 mg
Tablet, delayed releaseOral10 mg
SyrupOral9.78 mg/3mL
SyrupOral9.75 mg/5mL
Tablet25 MG
Tablet30 mg
Kit; tabletOral
KitOral
Powder, for solutionOral
Tablet, coatedOral25 mg
TabletOral
SyrupOral12.5 mg/30mL
Syrup100 mg/100mL
LiquidOral
Prices
Unit descriptionCostUnit
Doxylamine succinate powder1.5USD g
Unisom sleep aid tablet0.34USD tablet
Sleep aid 25 mg tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6340695No2002-01-222021-06-21US flag
US7560122No2009-07-142019-01-25US flag
US9526703No2016-12-272033-02-18US flag
US9375404No2016-06-282033-02-18US flag
US9089489No2015-07-282033-02-18US flag
US9937132No2018-04-102033-02-18US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)139 °C at 5.00E-01 mm HgPhysProp
water solubility1 g/ml (succinate salt)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP2.9ALOGPS
logP2.96ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.36 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity82.24 m3·mol-1ChemAxon
Polarizability31.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9505
Blood Brain Barrier+0.9491
Caco-2 permeable+0.746
P-glycoprotein substrateSubstrate0.7449
P-glycoprotein inhibitor INon-inhibitor0.5123
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7507
CYP450 2C9 substrateNon-substrate0.8153
CYP450 2D6 substrateNon-substrate0.5432
CYP450 3A4 substrateSubstrate0.6801
CYP450 1A2 substrateNon-inhibitor0.9092
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorInhibitor0.8361
CYP450 2C19 inhibitorNon-inhibitor0.8764
CYP450 3A4 inhibitorNon-inhibitor0.6894
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.736
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9218 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8765
hERG inhibition (predictor II)Inhibitor0.5398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0ab9-9200000000-5a71de62862f9881c2a1
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0040-0956300000-af11cf85a674e7db3735
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-001i-0910000000-b3cb895f045d519f2bf3
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-00kb-5597500000-8495062a84b32e776f33
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1920000000-07b98b36c7ef5d9ad048
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-1ae1143763892a7aac22
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-460d58a5bb6a5eb5f55b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0159-0900000000-34dc5c06413efae437da
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-8a5f15b863b7129c1288
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-072ffba5139b7324d27a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lr-0900000000-fdf3fc57eff19bfe8fd8
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Doxylamine at toxic doses can cause anticholinergic effects.
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Syed H, Som S, Khan N, Faltas W: Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. BMJ Case Rep. 2009;2009. pii: bcr09.2008.0879. doi: 10.1136/bcr.09.2008.0879. Epub 2009 Mar 17. [PubMed:21686586]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Curator comments
Antagonist at the canonical form of the receptor. Agonist at isoform 3 of the receptor.
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
Curator comments
Doxylamine was found to induce CYP2B enzymes in mice; correlation with human subjects has not been established.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Not Available
Gene Name
CYP2B
Uniprot ID
Q14097
Uniprot Name
CYP2B protein
Molecular Weight
43147.81 Da
References
  1. Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A: Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. [PubMed:8975784]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2020 01:55

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates